(Reuters) – The U.S. Food and Drug Administration said on Wednesday Eli Lilly and Co’s COVID-19 drug bebtelovimab is not currently authorized for emergency use in the country as it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
